Alex Pasteur - Profile and Investment Details

Investor Profile

Alex Pasteur is a Venture Capital, Private Equity Firm, Finance Operator, Investor based in London, England, United Kingdom with a diverse investment portfolio that includes companies such as Pulmocide, Oviva, Adaptimmune, Orchard Therapeutics (NASDAQ: ORTX) acquired by Kyowa Kirin in 2023, Acacia Pharma (EURONEXT BRUSSELS: ACPH) acquired by Eagle Pharmaceuticals in 2022, Genomics, Tenpoint Therapeutics, Ltd., NodThera, Castor, Shift Bioscience, Arvelle Therapeutics (Acquired by Angelini Pharma in 2021), ARTBIO, Owkin, Acacia Pharma, . Over time, Alex Pasteur has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Alex Pasteur is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Drug Discovery, Wellness, Enterprise Software, Android, Life Science, Engineering, Banking, Information Technology (IT), Supercomputing, Finance, Software, Biotechnology, Drug Development, Electronic Health Records (EHR), Health and Hospital Services, FinTech, Research, Reviews and Recommendations, Consumer Software, High-Performance Computing, Medical, Big Data, Information Technology, B2B, Media and Entertainment, Machine Learning, Pharmaceuticals may find it worthwhile to explore potential connections with Alex Pasteur, as their portfolio suggests a familiarity and interest in this area.

Understanding Alex Pasteur’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.